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A translational research framework for enhanced validity of
mouse models of psychopathological states in depression
Abstract
Depression presents as a disorder of feelings and thoughts that debilitate daily functioning and can be
life threatening. Increased understanding of these specific emotional-cognitive pathological states and
their underlying pathophysiologies and neuropathologies is fundamental to an increased understanding
of the disorder and, therefore, to development of much-needed improved therapies. Despite this, there is
a current lack of emphasis on development and application of translational (i.e. valid)
neuropsychological measures in depression research. The appropriate strategy is neuropsychological
research translated, bi-directionally, between epidemiological and clinical human research and in vivo -
ex vivo preclinical research conducted, primarily, with mice. This paper presents a translational
framework to stimulate and inform such research, in four inter-dependent sections. (1) A depression
systems-model describes the pathway between human environment-gene (E-G) epidemiology,
pathophysiology, psycho- and neuropathology, symptoms, and diagnosis. This model indicates that
G-->emotional-cognitive endophenotypes and E-G/endophenotype-->emotional-cognitive state markers
are central to experimental and translational depression research. (2) Human neuropsychological tests
with (potential) translational value for the quantitative study of these endophenotypes and state markers
are presented. (3) The analogous rodent behavioural tests are presented and their translational validity in
terms of providing analogue emotional-cognitive endophenotypes and state markers are discussed. (4)
The need for aetiological validity of mouse models in terms of G-->endophenotypes and E-G-->state
markers is presented. We conclude that the informed application of the proposed neuropsychological
translational framework will yield mouse models of high face, construct and aetiological validity with
respect to emotional-cognitive dysfunction in depression. These models, together with the available
technological tools, can then be studied to increase understanding of depression pathophysiology and
neuropathology, leading to identification and validation of novel therapeutic targets and the
development of effective, personalized antidepressant treatments.
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Summary 
Depression presents as a disorder of feelings and thoughts that debilitate daily functioning and can 
be life threatening. Increased understanding of these specific emotional-cognitive pathological states 
and their underlying pathophysiologies and neuropathologies is fundamental to an increased 
understanding of the disorder and, therefore, to development of much-needed improved therapies. 
Despite this, there is a current lack of emphasis on development and application of translational (i.e. 
valid) neuropsychological measures in depression research. The appropriate strategy is 
neuropsychological research translated, bi-directionally, between epidemiological and clinical human 
research and in vivo - ex vivo preclinical research conducted, primarily, with mice. This paper 
presents a translational framework to stimulate and inform such research, in four inter-dependent 
sections. (1) A depression systems-model describes the pathway between human environment-gene 
(E-G) epidemiology, pathophysiology, psycho- and neuropathology, symptoms, and diagnosis. This 
model indicates that G → emotional-cognitive endophenotypes and E-G/endophenotype → 
emotional-cognitive state markers are central to experimental and translational depression research. 
(2) Human neuropsychological tests with (potential) translational value for the quantitative study of 
these endophenotypes and state markers are presented. (3) The analogous rodent behavioural tests 
are presented and their translational validity in terms of providing analogue emotional-cognitive 
endophenotypes and state markers are discussed. (4) The need for aetiological validity of mouse 
models in terms of G → endophenotypes and E-G → state markers is presented. We conclude that 
the informed application of the proposed neuropsychological translational framework will yield 
mouse models of high face, construct and aetiological validity with respect to emotional-cognitive 
dysfunction in depression. These models, together with the available technological tools, can then be 
studied to increase understanding of depression pathophysiology and neuropathology, leading to 
identification and validation of novel therapeutic targets and the development of effective, 
personalized anti-depressant treatments. 
Keywords: Major depressive disorder, neuropsychology, translational research, environment-gene, 
stress, endophenotype, state marker, molecular target 
3 
 
1. Introduction 
The mental disorder depression is a leading cause of suffering, disability and economic burden 
worldwide (Murray and Lopez, 1997; Kessler et al., 2005). To-date, the considerable research into 
depression has failed to identify a single molecular entity, which has then been targeted 
pharmacologically to lead to the development of a novel antidepressant therapy. The current 
generation of antidepressant therapies, the selective monoamine reuptake inhibitors, is derived from 
the tricyclic antidepressants, such as imipramine, and the monoamine oxidase inhibitors, the 
antidepressant properties of both of which were discovered serendipitously (Pletscher, 1991). The 
primary mechanism-of-action of tricyclic antidepressants is to inhibit the pre-synaptic reuptake of 
serotonin and noradrenaline by their respective transporter proteins, and the selective monoamine 
reuptake inhibitors have this same mechanism-of-action. Whilst the selective monoamine reuptake 
inhibitors have, relative to tricyclic antidepressants, yielded clinical progress in terms of reduced side 
effects and increased patient adherence, they are suboptimal in terms of: latency to onset of effect, 
efficacy relative to placebo in terms of remission and recovery (being ineffective in many patients), 
and efficacy in terms of prevalence of relapse (Kirsch et al., 2008; Fournier et al., 2010). This sub-
optimal efficacy of the selective monoamine reuptake inhibitors is perhaps not surprising given the 
serendipitous discovery of their mechanism-of-action. Accordingly, there is a marked need for one or 
more novel antidepressant therapies with a mechanism-of-action based on goal-directed research. 
This situation leads to the central questions of: why have efforts failed to-date, and what changes in 
research strategy could prove to be critical in turning past and current failure into future successful 
depression target discovery and antidepressant development? 
It is, of course, not novel to propose that the answers to these questions lie within the scope 
of translational research, defined here as a bi-directional transfer of epidemiological and clinical 
knowledge on the nature and causes of depression to animal (preclinical) models, and the transfer of 
mechanistic and neuropharmacological preclinical knowledge back to depressed patients. What is 
novel in the current paper is the emphasis placed on the need for improved neuropsychological 
translational validity of preclinical models in depression and antidepressant research. Specifically, the 
need for improved validity of the tests used to measure animal behaviour/neuropsychology, and of 
the gene polymorphisms and environmental factors, and their combined effects, which predispose 
to, trigger and maintain depression-relevant states in these behavioural tests. However, before 
describing and justifying the advances that are essential at the preclinical level, it is important to 
describe the current neuropsychological research efforts towards promoting depression 
understanding at the clinical level. The starting point for this is a summary of the symptoms and the 
classification/diagnosis of depression. 
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2. Depression 
2.1. Depression symptoms and nosological diagnosis 
Depression is a disorder of feelings, thoughts and somatic functions. It presents as a number 
of heterogeneous emotional, cognitive and motor symptoms, where the clinical assessment of 
whether and which symptoms pertain is based on the patient’s (and possibly also a relative’s) verbal 
report to the clinician’s interview as well as on the clinician’s direct observations (DSM-IV, 1994). 
Depression is diagnosed using nosological classification, i.e. where a disease or disorder is envisaged 
as a discrete entity characterized by specific symptoms that: are each scored in an all-or-none 
manner, tend to co-occur together, follow a certain course and have a certain outcome and, in 
principle but rarely in practise in mental disorders, are underlain by a recognised neuropathology 
(van Praag et al., 2004). Two nosological classification systems exist for depression disorders, as for 
the other psychiatric disorders, and these are the Diagnostic and Statistical Manual of Mental 
Disorders (DSM), 4th edition, text revision (DSM-IV, 1994) and the International Classification of 
Diseases (ICD), 10th edition, chapter V: Classification of Mental and Behavioural Disorders (ICD-10, 
1994). Both of these nosolological classification systems are widely accepted and applied, primarily 
using DSM, as the bases of psychiatric diagnosis. Within “depression” both DSM and ICD recognise 
several forms of depressive disorder and grades of severity within these forms. According to DSM, 
major depressive disorder (MDD) is the most common form of depression, and an approximate 
equivalent of MDD in ICD is (recurrent) moderate depressive episode. The typical symptoms that 
must (obligate) and common symptoms that can (facultative) pertain to lead to a nosological 
diagnosis of MDD, according to DSM and its approximate ICD equivalent, are listed in Table 1. Thus, 
according to DSM, MDD will be diagnosed if the clinical course is one or more major depressive 
episodes, with each such episode characterised by five (or more) symptoms during a minimum 2-
week period, where at least one of the symptoms is either depressed mood (sadness, emptiness) or 
anhedonia (loss of interest or pleasure in (almost) all activities). According to ICD-10, (recurrent) 
moderate depressive episode will be diagnosed if the clinical course is one (or more) episodes during 
a minimum 2-week period of at least two of the three typical symptoms i.e. depressed mood, loss of 
interest and enjoyment, reduced energy leading to increased fatigability and diminished activity, and 
at least three (preferably four) of the other, common symptoms (Table 1).  
    TABLE 1 ABOUT HERE PLEASE 
Based on describable and observable symptoms, the DSM and ICD nosologies allow for 
relatively clear diagnosis of, and unambiguous communication about, MDD. However, it is equally 
clear that the clinical entity MDD: is a composite of heterogeneous symptoms; these symptoms will 
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vary in severity within and between patients, but, in the nosology, are depicted as all-or-none; exists 
without reference to its neuropsychopathology1; the neuropsychopathology will be different for the 
different symptoms. Simply put, the heterogeneous nosological entity of MDD is not an entity based 
on pathology, and because of its heterogeneity and all-or-none nature is not an entity that can be 
studied in terms of its pathology. As such, there is incompatibility between the current diagnostic 
system and psychological and neurobiological research that would aim to increase understanding of 
MDD neuropsychopathology and, based on this, could lead to development of novel, improved 
treatments. This situation is schematized in Figure 1: a diagnosis of MDD will inform very little about 
the specific psychological dysfunctions and concomitant neurobiological changes that underlie the 
patient’s major symptoms. The responses of the individual symptoms and their underlying 
psychological functions to the chosen course of treatment cannot be monitored. Little will be learned 
in terms of treatment responses and non-responses of the symptoms/psychological functions that 
can be used to increase understanding of their aetiology, and therefore could be used to inform 
research and development into novel treatments.2 
    FIGURE 1 ABOUT HERE PLEASE 
The lack of quantification in the nosological diagnosis of MDD has stimulated the 
development of rating scales, most prominently the Hamilton Depression Rating Scale (Ham-D) 
(Hamilton, 1960) and the Beck Depression Inventory (BDI) (Beck et al., 1961). Both Ham-D and BDI 
are based largely on the same symptoms as those used in DSM and ICD; in addition, in Ham-D, 
somatic factors, e.g. gastrointestinal complications and diurnal variation, are also added as 
symptoms, and in BDI, somatic preoccupation and loss of libido are added. In the Ham-D, scores are 
attributed to each symptom/category by the physician based on the patient’s verbal report and the 
physician’s observations. In the BDI, scores are attributed to each symptom/category based on the 
patient’s responses to the structured questions in the inventory. There is no doubt that the Ham-D 
and BDI are extremely important instruments in the clinic and to some extent at the interface of 
clinical research and the development of MDD therapies. Thus, they allow for quantitative 
assessment of therapy efficacy, both for each individual patient and in trials of developmental 
                                                          
1
 Here we use the term neuropsychopathology to describe the changes at the levels of psychology/behaviour, 
brain circuitry, and inter-cellular and intra-cellular brain functions, which causally underlie the symptoms of 
MDD. 
2
 Some integration of the focus on specific symptoms and their underlying neuropathology – a dimensional 
diagnosis approach - is indeed being considered for the upcoming revision of the DSM (Hyman, 2007). 
Therefore, this aspect of our translational framework is commensurate with current classification efforts in 
psychiatry. 
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compounds relative to placebo and existing reference-standard therapies (e.g. (Kirsch et al., 2008; 
Fournier et al., 2010). However, if a patient is resistant to her/his current therapy then the Ham-D 
score will, by definition, remain high, meaning that most symptoms were resistant to treatment. No 
insight will be gained because, as with the DSM and ICD classifications, an overall rating on the scale 
will not be helpful in terms of identifying the specific psychological dysfunctions and concomitant 
neurobiological changes that underlie the patient’s major symptoms and treatment resistance.  
2.2. From depression symptoms to emotional-cognitive states 
The paucity of the epistemological relationship between current depression diagnosis based 
on DSM or ICD and its neuropsychopathology is exemplified by the fact that one of the major, 
obligate symptoms of depression is depressed mood. Of course, this tautology raises the question of 
what, then, is depressed mood? Scientific understanding of mood is derived from emotion theory 
and, more recently, affective neuroscience. According to emotion theory, emotions e.g. sadness, 
helplessness, grief, pleasure, are distinct psychological states that vary in intensity and that arise in 
response to environmental stimuli or events that are either aversive or rewarding as processed by 
the brain’s punishment system and reward system (Rolls, 2000). Cognitive processes enable the 
individual in her/his emotional categorization of the environmental stimulus/event. Cognitive 
processes also allow an environmental stimulus/event to be re-experienced, or ruminated on, in the 
absence of its physical presence. Environmental stimuli or events are not absolute in their emotional 
valence; rather, emotional valence is individual-specific. In the case of each individual, the emotional 
response to a stimulus/event is determined by: his/her alleles for genes that regulate emotional 
responsiveness; the expression levels of these alleles and their products in the specific brain regions 
that constitute emotional-cognitive circuits; and his/her life history with respect to prior emotional 
experiences (Caspi and Moffitt, 2006; Jacobs et al., 2006). Thus, the extent to which an aversive 
stimulus activates the punishment system and elicits an emotion such as sadness, or the extent to 
which a rewarding stimulus activates the reward system and elicits an emotion such as pleasure, will 
depend on current and prior experience as determined by genetic and environmental factors 
(Berridge and Robinson, 2003; Cools et al., 2007). Given that these same genetic and environmental 
factors determine personality, then personality is logically also a major predictor of emotional 
reactivity. Mood or mood state refers to the general emotional experiences, and therefore 
disposition, of an individual at a typical time point within a certain time period, e.g. day, week, 
month. It might be that the mood of an individual can be linked to one or more identifiable major 
emotional events in the past, and that this might be, reactively, dominating emotional processing in 
the present, but this is not necessarily the case.  
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As will be clear from the above, the punishment system and reward system of the brain are 
the bases of emotions, and emotions are the bases of mood. Logically then, the punishment and 
reward systems are also the bases of mood. Returning to the above question, what is the depression 
symptom of depressed mood, this can be reformulated as: What dysfunction(s) of the brain’s 
punishment system result in its chronic hyper-sensitivity leading to the depression symptoms of e.g. 
sadness, pessimism, helplessness (Elliott et al., 2002) ? Using a similar logic, the other typical obligate 
DSM and ICD symptom of reduced interest and pleasure needs to be viewed as dysfunction in the 
brain’s reward system, resulting in its chronic hypo-sensitivity to typically rewarding stimuli and 
events. 
Therefore, it is quite straightforward to conduct a discourse between the terminology of 
psychiatric diagnosis and the corresponding terminology of emotion theory and affective 
neuroscience. This is extremely important because this interface provides the link between clinical 
practise with its current limited understanding of and success in treating MDD on the one hand and, 
on the other, research efforts that aim to increase understanding of and thereby develop improved 
treatments for MDD. This interface allows for the shift from MDD as an absolute, abnormal 
emotional-cognitive state, to MDD as several emotional-cognitive states that are each at the relative 
extreme end of their continuous distribution (Hyman, 2007). By analysing and understanding 
diagnostic terms such as helplessness, fatigue, absence of pleasure, with respect to their psycho- and 
neuro-pathology, insights will be gained into: their contribution to MDD; the value of their treatment 
to the treatment of MDD as a whole; and the neurobiological targets that can mediate successful 
treatment. The clear implication of this is that MDD research can only be realistically conducted at 
the level of individual symptoms or states. 
So far, this section has summarised the relationship between MDD as a single clinical 
disorder and MDD as a constellation of dysfunctional emotional-cognitive and associated somatic 
states. The next sub-section provides a summary of the current major evidence for the aetiology of 
MDD as a diagnostic entity as well as of certain of its constituent emotional-cognitive 
symptoms/states specifically. In close conjunction with the evidence for aetiological factors, we 
introduce a classification at the interface of the aetiology and the 
neuropsychology/neuropsychopathology of MDD. This classification, namely of endophenotype - 
state marker - symptom, is central to the framework proposed here for informing translational 
research in MDD. A systems model depicting these key concepts and their inter-relationships, is 
given in Figure 2. 
    FIGURE 2 ABOUT HERE PLEASE 
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2.3. Genetic and environmental aetiology of depression endophenotypes and state markers 
Major depression disorder is associated with specific genetic polymorphisms (G), life stress 
events (E), and life stress event x genetic polymorphism interactions (ExG) (Caspi and Moffitt, 2006). 
Integrating this evidence for the complex aetiology of MDD with the evidence, reviewed above, for 
MDD as a constellation of heterogeneous emotional-cognitive and somatic dysfunctions, indicates 
that an aetiology-based classification of dysfunction will be heuristically advantageous, if not 
essential. Accordingly, here we use the term MDD endophenotype to describe a psychological or 
neurobiological characteristic that is non-pathologic but increases the individual’s susceptibility to 
MDD. In terms of causality, endophenotypes are associated predictively with a specific gene 
polymorphism (G) or specific constellation of gene polymorphisms (GxG). Endophenotypes can be 
affected by environmental factors but, per the definition used here, not by the life stress events that 
are themselves associated with MDD. We use MDD state marker to describe a pathologic 
psychological or neurobiological characteristic that underlies or constitutes (an) MDD symptom(s). 
State markers are associated with life stress events (E) that increase the risk of MDD, and in 
particular with life stress event x specific gene polymorphism/endophenotype interactions (ExG). 
This aetiology-pathology heuristic model, also schematised in Figure 2, provides the background for 
the brief review of the current evidence for MDD aetiology which follows.3 
The heritability of MDD is estimated to be about 40% and therefore moderate (Sullivan et al., 
2000). A number of genetic-epidemiology studies have been undertaken to study for association 
between specific gene polymorphisms and MDD. These have all been a priori case-control 
association studies of candidate genes, with candidacy based on polymorphism and an a priori 
hypothesis, typically relating to monoaminergic or neurotrophic central nervous system (CNS) 
signalling. Based on recent meta-analyses of these studies, there is evidence for statistically-
significant association of a specific polymorphism with MDD for six genes: serotonin transporter (5-
HTT, SLC6A4), dopamine transporter (DAT, SLC6A3), dopamine receptor D4 (DRD4), 
methylenetetrahydrofolate reductase (MTHFR), guanine nucleotide binding protein (G protein) beta 
polypeptide 3 (GNB3), and apolipoprotein (APOE) (Levinson, 2006; Lopez-Leon et al., 2008). 
Hypothesis-free study based on genetic linkage has only recently been applied to MDD (Levinson, 
2006), and the systematic genome-wide study of association of polymorphisms, including single 
nucleotides and copy number variants, has not yet been conducted for MDD. 
                                                          
3
 “Endophenotype” and “state marker” have been introduced and applied separately as heuristic concepts in 
medicine/psychiatry by various authors (e.g. Gottesman and Shields, 1973; Van Praag, 1997; Gottesman and 
Gould, 2003; Caspi and Moffitt, 2006). 
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Given that MDD is a multi-factorial and heterogeneous entity, then epidemiological genetic 
evidence for a main-effect association of a specific, single polymorphism with MDD would actually be 
expected to be rare. From another perspective, the absence of a gene-MDD association could well be 
misleading with respect to its association with specific MDD endophenotypes or state markers. 
Clearly, psychological and neurobiological endophenotypes are the appropriate phenotypic level at 
which to identify novel risk genes and study their functional effects (Caspi and Moffitt, 2006; Walters 
and Owen, 2007) (Figure 2). An interesting example of this is provided by 5-HTT: one polymorphism 
of this gene is in the form of absence (“short”, s) or presence (“long”, l) of a base-pair segment within 
the 5-HTT gene-linked polymorphic region (5-HTTLPR) in the gene’s transcriptional control region. 
The short polymorphism, 5-HTTLPR-s, is associated with reduced 5-HTT expression and resultant 
reduced 5-HT presynaptic reuptake (Murphy and Lesch, 2008). Healthy 5-HTTLPR-s individuals 
exhibit, relative to healthy 5-HTTLPR-l individuals, increased anxiety- or mood-related 
temperamental traits (neuroticism) (Lesch et al., 1996), increased amygdala reactivity to angry faces, 
and low connectivity in the negative feedback circuit between perigenual cingulate and amygdala 
that correlates with slow extinction of negative emotions (Pezawas et al., 2005; Canli and Lesch, 
2007) (see next section for description of neuropsychological endophenotypes and state markers). A 
second reason why a lack of main-effect association of a gene polymorphism with MDD could well be 
misleading in terms of MDD aetiology, is that MDD state markers and symptoms are associated with 
ExG. Therefore, longitudinal genetic-epidemiology studies in which genome-wide association analysis 
is combined with environmental factor analysis are essential, so that ExG/endophenotype 
interactions that associate with MDD state markers can be identified (Figure 2). 
 Clearly, the meaningful study of ExG requires not only the identification of risk genes using a 
G → endophenotype strategy, but also the identification and quantification of the salient 
characteristics of environmental MDD-risk factors. In broad terms, the E’s most salient to MDD 
aetiology are stressors. Environmental stressors associated with MDD comprise stressors occurring 
during development (e.g. childhood abuse, neglect) and adulthood that increase vulnerability to 
MDD and stressors occurring more proximate to the onset of MDD and that could trigger the 
disorder (Brown et al., 1995; Kendler et al., 2002; Monroe and Reid, 2008). It is imperative to 
scientific rigour that, in epidemiological studies, stressors are measured prospectively and 
objectively. However, it is a substantial challenge to study stressful life events that occur in the 
contexts of e.g. employment, finance, housing, health, social relationships, with the aims of 
identifying which of these events are relevant to MDD and, if relevant, what their salient features are 
(Agid et al., 2000; Monroe and Reid, 2008). The adverse life event categories identified in one major 
MDD study were: death of a loved one, ending of a romantic relationship, personal failure or 
abandoned goal, chronic stress (due to work, finances, legal problems, etc), one’s own health 
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problems, interpersonal conflict between self and other, distress over future events (Keller et al., 
2007). It has been proposed that the most MDD-relevant stressful life events: involve threat, loss or 
humiliation; are very threatening or unpleasant; are experienced by the person directly; and are of 
distinct onset i.e. acute. If such E’s are associated with MDD, then they have typically occurred within 
3-6 months prior to MDD onset (Brown et al., 1995; Monroe and Reid, 2008). Uncontrollability is 
another important stress factor: experiencing uncontrollable stress can lead to altered activity in 
stress neurocircuitry and this, depending on genotype → endophenotype, could lead to MDD 
characterized by the perception of all stressors as uncontrollable, i.e. exposure to uncontrollable 
stress both causes and characterises MDD (see next section). In the study of Keller et al. (2007), the 
different adverse life events were significantly associated with different MDD symptoms: for 
example, death of loved ones and romantic breakups were marked by high levels of sadness, 
anhedonia, appetite loss; chronic stress and personal failure were associated with fatigue and 
hypersomnia. 
In laboratory research, psycho-stressors have been identified and incorporated into tests for 
the study of their acute impact in healthy subjects with or without specific risk genotypes, and in 
depressed patients (see next section). Examples include: uncontrollable painful stimuli (Bolz and 
Giedke, 1981; Strigo et al., 2008; Diener et al., 2009), uncontrollable cognitive stimuli (Elliott et al., 
1996; Michopoulos et al., 2006; Vasic et al., 2008), pictorial facial expressions of anger (Pezawas et 
al., 2005), unexpected negative feedback (Taylor Tavares et al., 2008), and temporally unpredictable 
stimuli (Herry et al., 2007). An additional important example is aversive social challenge e.g. the Trier 
social stress test (Kirschbaum et al., 1993). It is essential to clarify whether these stressors - which do 
indeed yield increased reactivity in depressed patients relative to healthy controls - share salient 
features with life stress events that can lead to MDD. 
In terms of the current clinical evidence for ExG → MDD association, probably the most 
striking example to date is the interaction between the 5-HTT gene-linked polymorphic region (5-
HTTLPR) and adulthood stressful life events: In a long-term prospective epidemiological study in New 
Zealand, young adults with one or two copies of the short (s) allele of 5-HTTLPR (5-HTTLPR-s) who 
experienced ≥3 adult stressful life events (SLEs) were significantly more likely to develop MDD (30% 
prevalence) than individuals with 5-HTTLPR-s x <3 SLE (10%), 5-HTTLPR-l x ≥3 SLE (15%) or 5-HTTLPR-l 
x <3 SLE (10%) (Caspi et al., 2003, see also Cervilla et al., 2007). The SLEs taken into account were 
those experienced at age 21-26 years and could occur within the contexts of employment, finance, 
housing, health, and social relationships. In a separate analysis of the same study cohort, 
experiencing severe maltreatment during childhood also increased the prevalence of MDD in s-allele 
carriers specifically. The longitudinal, prospective nature of this study, together with the careful 
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methods used to measure stressful life events, render it challenging to replicate. Indeed, several 
subsequent retrospective studies have failed to do so and there is actually only limited support for 
the 5-HTTLPR-s x SLE → MDD association from meta-analysis (Munafo et al., 2009; Risch et al., 2009). 
Suffice to note here that, in the future, the most informative ExG association studies will be 
prospective, will score and analyse stressors objectively, and will focus on psycho- and 
neuropathology state markers of MDD rather than on MDD as a (heterogeneous) nosological entity 
(Figure 2). With respect to psychopathology state markers, automated tests based on nonverbal 
responses to stimuli of emotional (aversive, rewarding) significance, allow for sensitive, quantitative 
(dimensional) analysis of emotional-cognitive processes; a number of such tests have been 
developed that are highly relevant to MDD, as discussed next. 
2.4 Neuropsychological tests for MDD emotional-cognitive endophenotypes and state markers 
Tests of neuropsychological processes have been developed to yield data relevant to a 
number of neurodegenerative and psychiatric disorders, including MDD. These tests are automated 
and thereby enable fine control of stimulus presentation and subject responses. Such tests provide 
valuable state markers for the disorder; they can also be of immense clinical value in terms of 
assessing disorder course, and even in diagnosis. Probably the best example of the latter to-date is 
the paired-associates object-in-space memory test for the early detection of Alzheimer’s dementia 
(O'Connell et al., 2004). For MDD, In order that an automated behavioural test can be regarded as 
probing a relevant neuropsychological process (endophenotype or state marker), then this process 
must: (1) have a clear theoretical relationship to one of the MDD symptoms, and (2) have different 
values, in the predicted direction, in MDD patients exhibiting the related/dependent symptom 
relative to healthy probands, and within individual patients during an MDD episode versus remission. 
When such a test has been validated in this way, it can then also be used as (3) a test for the same 
process, probably at a reduced level of divergence from control values, as an endophenotype, and 
therefore to assess the association of this psychological measure with candidate MDD-risk 
genotypes. In addition to their potential to provide important insights into the psychopathology of 
MDD, (4) automated psychological tests can be combined with molecular imaging methods thereby 
allowing for the study of the neuropsychology and neuropsychopathology of the states underlying 
MDD. Another advantage of automated psychological testing, and that which is a major focus of this 
paper, is that (5) versions of these tests can be developed for the translational study of the analogous 
psychological processes in laboratory animal species. It is also important to note that some of these 
tests measure processes that are not relevant to MDD specifically, but also to the anxiety disorders, 
such as generalised anxiety disorder and post-traumatic stress disorder, with which MDD is 
frequently co-morbid according to current nosological classifications. 
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In automated tests for psychological endophenotypes and psychopathological state markers 
in MDD, the approach will typically be to measure either a proband’s spontaneous responses to 
emotionally-salient stimuli, or a proband’s operant responses to neutral stimuli associated with 
emotionally-salient events. The design of such tests needs to be based on and informed by the 
obligate/core symptoms of depressed mood and loss of interest or pleasure (Table 1) which, as was 
discussed in section 2.2, are readily amenable to deconstruction in terms of discrete emotional-
cognitive processes. Certain of the facultative/common symptoms are also readily amenable to 
specific emotional-cognitive interpretation. This is particularly so for feelings of worthlessness (DSM) 
and reduced self-esteem and self-confidence (ICD) (Table 1): these symptoms are highly 
commensurate with the psychological concepts of learned helplessness, stress uncontrollability and 
learned irrelevance, for which automated tests have been developed (see below). The same 
importance of quantitative assessment methods applies to the MDD symptoms that do not, at least 
directly, reflect emotional dysfunction e.g. insomnia, psychomotor retardation or agitation. We now 
proceed to present some automated tests of neuropsychological processes that satisfy the five 
criteria stated above and illustrate the central importance of automated neuropsychological testing 
to the experimental and translational approach that will enhance understanding and treatment of 
MDD. These tests, the symptoms to which they are relevant, and, for later discussion, the analogous 
tests in the mouse, are given in Table 2. 
     TABLE 2 ABOUT HERE PLEASE 
Emotional and motivational reactivity to rewarding stimuli. Neuropsychological tests of 
individuals’ emotional reactivity to rewarding stimuli are of direct relevance to the core MDD 
symptom of loss of interest or pleasure/enjoyment i.e. anhedonia (Table 2). Reward is a complex 
neuropsychological process, the understanding and study of which is facilitated by the recognition of 
two major sub-processes, namely: the emotional process of recognising and “liking” a stimulus with 
pleasurable attributes, and; the incentive-motivational process of “wanting” a stimulus with 
pleasurable attributes and behaving in a corresponding, goal-directed manner to obtain the stimulus 
(Berridge and Robinson, 2003). Reduced reward liking is primarily synonymous with the loss of (i.e. 
reduction in) the pleasure/enjoyment aspect of anhedonia, and reduced reward wanting with the 
loss of (reduction in) the interest aspect. Neuropsychological tests have been developed that allow 
for quantification of reward liking or reward wanting, and the neuropsychological profiles of healthy 
probands and, relative to these, MDD patients in these tests have been investigated. Measurement 
of reward liking has focussed primarily on verbal valence ratings of the pleasantness experienced 
when presented with pictorial images from an established inventory for which normative ratings are 
available, e.g. the International Affective Picture System (IAPS) (Lang et al., 1997). MDD patients with 
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high levels of anhedonia exhibited reduced ratings of positive images, but not of neutral images, 
relative to control subjects (Sloan et al., 2001; Mitterschiffthaler et al., 2002). A measure related to 
the liking valence attributed to a positive pictorial image is that of the ability to recognise an image as 
emotionally positive. Such a test can be based on a series of pictures of faces expressing gradually 
increasing intensity of a positive emotion e.g. happiness: MDD patients are impaired in their ability to 
recognise happy faces, requiring a more intense happy facial expression than do healthy controls 
(Joorman and Gotlib, 2006). Measurement of reward wanting has deployed cognitive tasks (e.g. 
working memory) with low-level financial pay-off contingencies e.g. a reward condition in which a 
subject earns $0.10 each time they make a correct response. By using neutral, rewarding and 
punishment contingencies, it is possible to study whether MDD patients exhibit a deficit in behaving 
so as to maximise their reinforcement and whether this is specific to the reward contingency and 
therefore likely to indicate a deficit in incentive motivation. Indeed, a deficit in performance during 
reward conditions specifically has been observed in MDD patients relative to control subjects 
(Henriques and Davidson, 2000). 
Reactivity to emotionally negative stimuli. MDD patients frequently report feelings of fear 
and anxiety (DSM-IV, 1994). This suggests that emotional reactivity to discrete aversive stimuli will be 
increased and will constitute an important (albeit non-specific) state marker for MDD (Table 2). 
Neuropsychological tests to quantify aversive emotional reactivity have been established using 
presentation of photographs of anonymous human faces expressing varying intensities of specific 
negative emotions e.g. sadness, fear (Nowicki and Carton, 1992). MDD patients who were impaired 
in their sensitivity to happy faces (see above) did not differ from healthy controls in their ability to 
identify sad or angry faces, suggesting that they were not more sensitive to faces expressing negative 
emotions (Joorman and Gotlib, 2006). At the neural level, functional magnetic resonance imaging 
(fMRI) studies have demonstrated increased amygdala reactivity (left-hemisphere specific or 
bilateral) to sad or fearful faces in MDD patients relative to controls, as well as reduction in amygdala 
reactivity in MDD patients following a course of antidepressant treatment (Sheline et al., 2001; Fu et 
al., 2004). A reliable finding in MDD patients is that they exhibit preferential processing of negatively 
toned stimuli in tests of attention and memory i.e. cognitive bias (Elliott et al., 2002; see Emotional-
cognitive reactivity to ambiguous stimuli). Another situation in which MDD patients exhibit increased 
reactivity to negative stimuli is in emotional-cognitive tasks where negative emotional distracter 
stimuli have to be ignored (filtered out) in order to perform a cognitive (e.g. memory) task that 
involves processing of neutral stimuli (e.g. (Gotlib and Krasnoperova, 1998)). 
Emotional-cognitive reactivity to aversive uncontrollability. MDD patients frequently report 
feelings of: hopelessness, helplessness, lack/loss of control over environmental events, inability to 
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cope (Beck et al., 1974) (Table 2). These psychological states would appear to be closely inter-related 
and, whilst they are not diagnostic symptoms of MDD, they would appear to be of substantial 
relevance to this psychiatric condition. Indeed, non-control over aversive stimuli/events could be a 
major environmental aetiological factor in MDD, and genetically- and/or environmentally-induced 
perceived non-control over stimuli/events (non-controllable and normally controllable) could be a 
major psychopathology in MDD. The term learned helplessness was introduced in experimental 
psychology as an explanation for the observation that animals exposed to inescapable electric shocks 
(i.e. aversive unconditioned stimuli) exhibit a subsequent deficit in escape or avoidance behaviour, 
relative to animals exposed to escapable or no electric shock. The learned helplessness test in mouse 
is described below, but it is important here to briefly outline the theoretical interpretation and MDD-
relevance of the phenomenon. Learned helplessness theory posits that animals can learn that 
environmental events occur independently of their responses; thus, just as operant learning theory 
proposes that subjects learn that their behaviour controls the stimulus/reinforcement, learned 
helplessness proposes that subjects learn that their behaviour cannot control the 
stimulus/reinforcement ((Seligman et al., 1971); see Section 3.3.). 
Human versions of the learned helplessness test have been developed by fairly direct 
translation of the aversive unconditioned stimulus pre-exposure stage of the animal learned 
helplessness test; that is, with subjects being exposed to either avoidable versus yoked unavoidable 
electroshocks or escapable versus yoked inescapable electroshocks. Human subjects are then 
assessed and compared in terms of neural, physiological and psychological state. In healthy subjects, 
exposure to unavoidable electroshocks did not induce, relative to avoidable-shock subjects, any 
affect on vascular arousal, or subjective feelings of fear or exhaustion. However, it did induce 
reduced vascular arousal and increased giving up on a follow-on cognitive test, correct performance 
of which was reinforced with noise-escape. The authors of this study infer a learned helplessness -
based cognitive mediating process via which subjects exposed to unavoidable shocks develop a 
learning set that their behaviour will be ineffective in controlling aversive stimulation (Hokanson and 
Sacco, 1976). In another learned helplessness study (Diener et al., 2009), this time in MDD versus 
healthy subjects, two auditory stimuli were presented, with Stimulus 1 preceding Stimulus 2, and 
Stimulus 2 being a conditioned stimulus for electroshocks. Controllability of the aversive stimulus via 
operant response differed across three successive conditions: Control, Loss of control (50% of trials); 
Restitution of control. Subjective ratings of controllability were similar in MDD and healthy subjects, 
being reduced during the Loss of control condition. Subjective ratings of helplessness and emotional 
unpleasantness were significantly increased in MDD versus healthy subjects across all three 
conditions, and were fairly similar across all three conditions within subject groups. MDD subjects 
exhibited relatively increased post-imperative negative variation of the electroencephalogram 
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relative to healthy subjects during loss of and restitution of control conditions (Diener et al., 2009). In 
another recent study, MDD and healthy subjects were compared in terms of their fMRI neural 
activity during a heat pain-anticipation period: MDD patients exhibited relatively high activity in the 
dorsal anterior cingulate cortex and the amygdala. In the MDD subjects only, amygdala activity 
correlated with the self-assessment score of helplessness feelings during the anticipation period, 
articulated as “There is nothing I can do to reduce the intensity of pain.” (Strigo et al., 2008). 
Learned helplessness is specific to situations in which the unconditioned stimulus is 
(perceived as) aversive and thereby stimulates emotional-stress systems. However, the theory has 
been extended to account for behaviour relative to rewarding stimuli by studying the effects of pre-
exposure to a lack of association between a neutral stimulus and reward on subsequent 
discriminatory learning of an association between that stimulus and reward. The effect of pre-
exposure to lack of association is to impair subsequent acquisition of the association, a phenomenon 
referred to as learned irrelevance (Maes et al., 2004). It can be hypothesized that MDD patients will 
exhibit increased learned irrelevance, as well as increased learned helplessness, due to an increased 
sensitivity to negative events, but this remains to be systematically investigated. 
In the original learned helplessness studies, with rats, it was demonstrated that 
uncontrollable electroshocks had more detrimental effects if delivered on an unpredictable 
compared with a predictable schedule, where predictability was provided by a tone conditioned 
stimulus (Weiss, 1971). Recent translational (human-mouse) studies have investigated the effects of 
exposure to predictably per se, by exposing subjects to neutral auditory stimuli presented on a 
predictable or unpredictable time schedule. Healthy subjects exposed to neutral sound pulses on a 
temporally unpredictable schedule exhibited relative amygdala hyper-activity and increased 
attentiveness to emotional faces (Herry et al., 2007), suggesting that the investigation of 
unpredictability, and related processes such as uncertainty, with respect to their ability to elicit and 
identify state markers of MDD, will be important (e.g. (Bach et al., 2010)). 
Emotional-cognitive response to negative feedback. Negative feedback refers to the subject 
performing an operant response and not obtaining a reward, perhaps associated with a no-reward 
(punishment) signal. The valence of any reward would be expected to be reduced in (anhedonic) 
MDD versus healthy subjects. Despite this confound it has still been possible to design a test of 
reactivity to negative feedback in which it can be demonstrated that MDD subjects exhibit increased 
sensitivity to withholding of reward (Cools et al., 2002) (Table 2). Using inherently neutral stimuli (S’s) 
presented on a touch-sensitive screen, subjects are instructed to maximise the positive feedback 
they obtain by learning and selecting the positive discriminatory stimulus (S+) i.e. that S which yields 
the feedback “Correct!”. On a probabilistic reversal learning test, the identity of S+ reverses after a 
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number of correct responses so that the previous S- now becomes S+, and vice versa. In addition, on 
some trials, about 20%, the subject receives misleading negative feedback i.e. choosing S+ yields 
“Incorrect!” feedback. MDD patients are hyper-sensitive to this misleading negative feedback in 
terms of their increased likelihood to exhibit lose-shift behaviour, i.e. to choose S-, on the next trial 
(Taylor Tavares et al., 2008). 
Emotional-cognitive reactivity to ambiguous stimuli. Reduced pleasure and interest and 
increased aversive reactivity as independent state markers of MDD have already been addressed 
above. A further marker is high bias to negative expectancy (Table 2), referring to the emotional-
cognitive assessment of ambiguous stimuli; that is, stimuli that could potentially be either rewarding 
or aversive because of the ambiguous sensory information that they relay. Cognitive biases in 
assessment of emotional stimuli can be grouped into various categories, such as attention bias, 
memory bias and judgement bias (Elliott et al., 2002; Paul et al., 2005). We would include attention 
and memory biases as examples of aversive reactivity (see above), and are concerned here with 
judgement bias with respect to emotional stimuli and the increased negative judgement bias 
reported for MDD patients. Emotional-cognitive judgement making includes assessment of 
ambiguous stimuli, expectations about the future, and risk-taking. For example, using subjective 
probability assessments of ambiguous situations, individuals in a sad mood overestimate the 
likelihood of negative outcomes and underestimate the likelihood of positive outcomes, relative to 
controls (Wright and Bower, 1992). On a verbal fluency paradigm to assess the ability of subjects to 
think of future positive and negative personal experiences, non-clinical subjects who were classified 
as anxious-depressed on scales derived from the Present State Examination exhibited both greater 
anticipation of negative experiences and reduced anticipation of positive experiences, relative to 
non-anxious, non-depressed probands (MacLeod and Byrne, 1996). 
Physical effort required to complete a manual test. The state of feelings of lack of energy and 
of fatigue is an important symptom of MDD (Table 1), and is at the interface of somatic, emotional 
and cognitive pathologies. Fatigue can be divided into components of psychomotor retardation, 
physical tiredness and mental fatigue (Demyttenaere et al., 2005) (Table 2). Such separation of 
fatigue into distinct components is important with respect to its quantification, but there have been 
relatively few attempts to develop specific tests. One test that has been used to quantify the physical 
tiredness component of fatigue is the measurement of grip strength using a dynamometer: MDD 
patients exhibit relatively rapid reduction of the grip strength of the right forelimb across trials of 
maximum grip strength. This co-occurs with a reduction in the right-left asymmetry of grip strength, 
and is associated with relative hypo-activation of the left anterior cortical region (Emerson et al., 
2001).  
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Following the framework of aetiology → endophenotype/state marker/symptom used above 
for human MDD research, then any mouse model of an MDD endophenotype or state marker also 
needs to comprise a combination of aetiological factors and phenotypic readout. Accordingly, a 
combination of a G, E or ExG manipulation with aetiological validity and a behavioural test with face 
and construct validity constitutes a translational mouse model of a MDD endophenotype or state 
marker. In Sections 3 and 4, respectively, some behavioural tests with demonstrated or potential 
construct/face validity and some genetic and environmental manipulations with demonstrated or 
potential aetiological validity, are presented. 
3. Mouse behavioural tests in translational depression research 
3.1. The central importance of valid behavioural tests in mouse models of depression 
 In the preceding sections the case for the importance of assessment of emotional-cognitive 
neuropsychological status in depressed patients has been presented. Depression is a disorder of 
feelings and thoughts, and we have described the inter-relationships (schematized in Figure 2) 
between the current diagnostic symptoms of MDD, the emotional-cognitive states that describe the 
psychopathology of MDD, and psychological tests that provide for quantification of these state 
markers, as well as of their neural correlates using functional imaging procedures. The aim of the 
current section is to describe the translational links, or “bridges”, that either already exist or can be 
developed, between these neuropsychological MDD state marker tests and equivalent tests in mice. 
Figure 3 presents this translational scheme: it takes the diagnosis - symptom - state marker - 
neuropsycho-patholgy scheme presented for MDD (Figure 2) and extends this to mice, proposing 
that translational state markers with analogous neural and psychological concomitants to those 
identified in human MDD, exist in mice. The critical step is then to develop tests for these mouse 
state markers that are valid with respect to the validity criteria that must be met by such tests.  
Table 2 lists the mouse tests that would be the equivalent to each of the human tests 
described above. The validity criteria of the behavioural tests, based on the terminology originally 
proposed and justified by Willner (Willner, 1984), are: (1) Face validity i.e. there must be a 
demonstrated emotional or emotional-cognitive phenomenological similarity underlying the 
respective state marker readouts of the mouse test and the human test to which it corresponds. 
Furthermore, the direction of the change (increase or decrease) in the readout in the manipulated 
versus control mice must be the same as that in the MDD versus control human subjects. (2) 
Construct validity i.e. the mouse-human face similarity must be underlain by similar psychological, 
physiological and neurobiological changes in the manipulated versus control mice and the MDD 
versus control human subjects. The additional validity criteria of (3) aetiological validity and (4) 
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predictive validity are presented in the appropriate sections below. In section 3.3 we describe the 
mouse tests which do or could, with further validation research, fulfill these validity criteria for the 
MDD translational state markers of interest, as listed in Table 2. Preceding this, a short summary is 
provided of some mouse behavioural tests that are currently commonly applied with the aim of 
measuring psychological states relevant to MDD and their pharmacological modulation. 
    FIGURE 3 ABOUT HERE PLEASE 
3.2. Current mouse behavioural tests: deficits in face and construct validity 
Due in part to the lack of emphasis on discrete endophenotypes and state markers in 
psychiatry it has, until recently, been extremely difficult for preclinical researchers to identify 
translational state markers and develop corresponding tests with face and construct validity (Willner, 
1997; Willner and Mitchell, 2002; Markou et al., 2009). Despite the new emphasis on 
endophenotypes and state markers there continues to be, however, a large number of mouse 
studies that are based on behavioural tests that have a proven relevance to MDD in terms of their 
readout being sensitive to antidepressant compounds rather than in terms of demonstrated face and 
construct validity. For example, the forced swim test and the tail suspension test in mice are still 
widely used in depression research to study the effects of compounds in drug discovery (i.e. 
screening) as well as the effects of genetic (G) and environmental (E) manipulations (for excellent 
reviews see (Cryan et al., 2005; Cryan et al., 2005)). The common application of the mouse forced 
swim test and tail suspension test is linked directly to the robust and reproducible effects of the 
current and previous generations of monoamine reuptake inhibitors on mouse behaviour in these 
tests. The effect of the existing monoamine reuptake inhibitor drug classes on mouse behaviour in 
these tests was demonstrated retrospectively (Porsolt et al., 1977). A test with demonstrated 
retrospective predictive validity is of course markedly different from a test that has demonstrated 
face and construct validity with respect to an MDD translational state marker, exhibits predictive 
validity with respect to reference antidepressants, and prospective predictive validity with respect to 
a new compound class in development that subsequently exhibits antidepressant efficacy with 
respect to one or more state markers/symptoms in clinical trials. Despite this and, specifically, 
despite the lack of demonstrated face or construct validity of the forced swim test or tail suspension 
test, these tests continue to be widely incorporated into studies.  
In both the forced swim test and tail suspension test, motor inactivity develops across time in 
the test, and this increase in inactivity is antagonised by acute or chronic administration of reference 
antidepressants. The neuropsychological mechanisms underlying both development and 
pharmacological antagonism of the observed inactivity are unclear. Behavioural despair resulting 
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from uncontrollable stressor exposure is often cited as the mediating mechanism (Porsolt, 2000). As 
will be clear from the central theme of this paper, the proposal that despair resulting from an 
uncontrollable stressor mediates mouse behaviour in the forced swim test and tail suspension test  is 
problematic. Specifically, this is because: (1) (Even) in humans, despair is multi-factorial and difficult 
to quantify. (2) There is no comparison group exposed to controllable stress. (3) The tests do not 
yield a measure of despair that is independent of the measure of inactivity, and therefore there is no 
possibility to separate despair from inactivity and to study their antidepressant responses separately. 
It would therefore be parsimonious to propose increased inactivity as the mediating mechanism in 
the test, and inhibition of increased inactivity as the mechanism of action of reference 
antidepressants on behaviour in the test.  
Therefore, mouse tests with potential predictive validity must have demonstrated face and 
construct validity and must, therefore, be based on translational state markers. Some existing such 
tests and potential future candidates are discussed in the next section. 
3.3. Mouse behavioural tests with face and construct validity for MDD endophenotypes and state 
markers 
For predictive (i.e. translational) research in MDD, mouse behavioural tests are required that 
deliver quantitative readouts which are unambiguous analogues of psychological endophenotypes 
and state markers of MDD. As will be clear from the above discussion of the forced swim test and tail 
suspension test readouts, establishing such face and construct validity demands that the 
psychological mediating mechanisms are identified and that potential alternatives are excluded. The 
mouse behavioural tests described here are the analogue tests of the human MDD enophenotype 
and state marker tests presented above, which were themselves selected because of their 
translational value or potential (see Table 2). Whilst the focus of this paper is translational 
psychological and psychopathological MDD research, it is clear that understanding psychological 
mechanisms is intimately related to and dependent on understanding neurobiological mechanisms. 
The neurobiological construct validity of the behavioural tests are not reviewed in detail below, but 
brief summaries are given and key references cited. 
Preference for palatable stimulus versus water. This type of test is proposed as an analogue 
of human tests that measure emotional reactivity to rewarding (visual) stimuli, and therefore as 
relevant to the obligate symptom of loss of pleasure/enjoyment (Table 2). The test is based on 
presentation of free consumption (i.e. without separate operant response) of a palatable gustatory 
stimulus, typically weak sucrose solution, versus neutral water in a discrimination-choice situation, 
followed by measurement of the relative consumption of the two solutions. The hypothesis is that 
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the sucrose preference ratio provides a measure of reward sensitivity or hedonic liking, such that a 
reduced sucrose preference will constitute an analogue endophenotype or state marker of loss of 
pleasure/emjoyment. The test was originally developed for studying the effects of exposure to 
chronic unpredictable mild stressors (see section 4.3 and Table 3) on their sucrose preference of rats 
(Willner, 1997). Rats exposed to chronic unpredictable mild stressors develop a reduction in their 
sucrose preference and this reduction is reversed gradually by chronic antidepressant administration. 
The test has been modified for mice and applied to study effects of chronic unpredictable mild stress 
and social defeat stress on their consummatory preference for sucrose versus water, and 
antidepressant effects thereon (Monleon et al., 1984; Krishnan et al., 2007). The neurobiology 
underlying preference for palatable solutions is well-described in rodents, but the changes 
underlying reduction in this preference less so (Berridge and Robinson, 2003). 
Operant responding for palatable stimulus on delayed reinforcement schedule. These tests 
are proposed as analogues of human tests that measure incentive motivation relative to rewarding 
stimuli, typically money, and that therefore assess reward wanting. They are therefore relevant to 
the loss of interest symptom in MDD (Table 2). Again, the unconditioned stimulus is gustatory-
palatable e.g. sucrose pellet, sucrose solution. In such tests the mouse is required to execute specific 
operant responses, e.g. nose pokes. First, the mouse is trained on the association between its 
operant response and delivery of reward. Then a delayed reinforcement schedule is introduced such 
that the effort of the delay between onset of responding and delivery of reward provides a measure 
of incentive motivation or hedonic wanting. Typical reinforcement schedules are the variable-interval 
schedule, where the interval between the previous reinforcement and the first operant response 
that will activate the next reinforcement is unpredictable, and the progressive-ratio schedule, where 
the subject must execute more operant responses for the next reinforcement than it did for the 
previous reinforcement (Davey, 1981). Such schedules require effort in terms of waiting time, 
operant effort, and coping with unpredictability. The hypothesis is that responding on such operant 
schedules provides a measure of incentive motivation/reward wanting; therefore, a relatively low 
rate of responding on a variable-interval or a progressive-ratio schedule or a relatively rapid giving up 
of responding on a progressive-ratio schedule, will constitute an analogue endophenotype or state 
marker of loss of interest. One confounding mediating mechanism that could also account for such 
readouts, and which would be relevant to MDD but not to anhedonia, would be an increased 
sensitivity to the negative feedback received during non-reinforced responses (see Emotional-
cognitive reactivity to negative feedback, below). In rats, the effects of early life stress on incentive 
motivation for reward in adulthood has been studied using operant responding for sucrose solution 
on a progressive-ratio schedule: early life stress as daily deprivation of social contact led to adults 
that exhibited reduced responding, and this effect was reversed by chronic antidepressant 
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(fluoxetine) administration (Ruedi-Bettschen et al., 2005; Leventopoulos et al., 2009). In mice, 
chronic corticosterone exposure has been demonstrated to lead to reduced operant responding for 
sucrose pellets on a progressive-ratio schedule; this effect was reversed by chronic antidepressant 
administration (Gourley et al., 2008). As with reward liking, the neurobiology underlying rodent 
incentive motivation for palatable stimuli is well-described in rodents, but the changes underlying 
reduction in this preference less so (Berridge and Robinson, 2003). 
Emotional reactivity to discrete stimuli and to contexts associated with innately negative 
(footshock) stimuli. When rats and mice are exposed to a novel environment/context and to a neutral 
discrete stimulus (e.g. tone, light) that predict, via classical conditioning, an aversive unconditioned 
stimulus in the form of brief inescapable electric foot shocks, they develop freezing behaviour, 
indicative of context- and discrete stimulus-conditioned fear. Primarily because of the pioneering 
studies demonstrating that the amygdala, most notably its basolateral and central nuclei, is a major 
mediator of these fear processes (LeDoux, 2000), fear-conditioned freezing provides an analogue for 
the human tests that measure aversive reactivity (Table 2). As noted above, the human tests used in 
MDD research involve subject sensitivity and amygdala reactivity to innate stimuli such as sad or 
fearful faces, so there is a distinct difference here in that the rodent tests are based on classical 
conditioning. There is construct validity with respect to MDD in that, certainly in rodents, the 
amygdala is the area in which conditioning occurs. Nonetheless, fear-conditioned freezing is 
particularly relevant to affective disorders such as specific phobias and post-traumatic stress 
disorder, and indeed can be used to study the development, consolidation, recall, extinction and 
reconsolidation of discrete stimulus- and context-conditioned fear (Blanchard et al., 2001). 
Two-way escape deficit after uncontrollable stress. This type of “learned helplessness” test is 
proposed as an analogue for human tests of emotional-cognitive reactivity to stimulus 
uncontrollability, and therefore as relevant to the MDD state marker of feelings of lack of control or 
helplessness (Table 2). Indeed the human tests are adapted from the animal tests and inescapable 
(uncontrollable) (IES) versus escapable (controllable) (ES) electroshock is deployed as the aversive 
US, or stressor, across species. In rodent tests, repeated pre-exposure to IES versus the same amount 
of ES and versus no electroshock (NS), leads to a subsequent deficit in escape behaviour, typically in a 
two-way shuttle arena escape test, in the IES group relative to the other two groups (ES, NS), which 
exhibit similar, high levels of escape behaviour.4 In rats, pre-exposure to electroshock has typically 
taken the form of tail shocks, which are terminated in the ES group by turning a running wheel with 
                                                          
4
 In contrast to the other tests presented in Table 2, this test includes prior exposure to an environmental 
stressor as an inherent component. According to the terminology used here, the test is therefore a model. 
Section 4 provides further explanation of this important distinction. 
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the forelimbs (Weiss, 1971). In mice, pre-exposure to electroshock has typically taken the form of 
foot shocks in the same environment as used in the escape test (Anisman and Merali, 2001). 
The deficient escape behaviour exhibited by the IES group is interpreted as a learned 
expectation that aversive stimuli occur independently of behaviour (Maier and Seligman, 1976). 
Nonetheless, the face and construct validity of the test needs to stand up to the same challenges as 
those used above to demonstrate the lack of validity of the forced swim test and tail suspension test 
(FST/TST) as tests of despair. A major advance of the learned helplessness test relative to FST/TST is 
that the deficit exhibited by the IES cohort is clearly due to stressor uncontrollability, this being the 
only difference between the stressor experienced by this cohort and the ES cohort. Another criticism 
raised above against FST/TST, and that has also been levelled against learned helplessness tests, is 
that it is unclear whether the escape deficit readout is due to motor inactivity per se or whether the 
motor deficit reflects an emotional-cognitive state based on learning that footshock is independent 
of behaviour. These alternative explanations are depicted in Figure 4A. Also with respect to this 
challenge of validity, the learned helplessness test has been much more rigorously studied than have 
the forced swim test and tail suspension test: Using a test of signalled-punishment suppression of 
operant behaviour, it has been demonstrated for learned helplessness rats that they also exhibit a 
subsequent deficit in behaviour-outcome expectancy in this test, in that they exhibit more operant 
responding, reflecting increased motor behaviour, during the conditioned stimulus that signals that 
operant responding will elicit foot shock as well as reward (Jackson et al., 1978). This triangulation 
approach - depicted in Figure 4B - provides strong evidence that impaired behaviour-outcome 
expectancy (i.e. an emotional-cognitive deficit) underlies the learned helplessness effect and that it is 
not confounded by motor inactivity. 
     FIGURE 4 ABOUT HERE PLEASE  
Regarding neurobiological mediation, rats that have experienced IES appear, relative to ES 
rats, to exhibit deficient inhibitory input from the ventromedial prefrontal cortex to the dorsal raphé 
nucleus. This would lead to the increased dorsal raphé serotonin ouput to cortico-limbic-striatal 
regions which has been demonstrated to occur in IES rats that then go on to exhibit a subsequent 
escape deficit. This finding suggests that the assessment within the ventromedial prefrontal cortex of 
the controllability of the stressor is a critical neurobiological mediator of controllability/helplessness 
(Amat et al., 2005). According to this hypothesis, experiencing uncontrollable stress can lead to 
reduced activity in the prefrontal cortex which, if this prefrontal cortex hypo-activity became chronic, 
could lead to a generalized state of perceiving all stressors as uncontrollable, i.e. exposure to 
uncontrollable stress both causes and characterises helplessness in MDD due to prefrontal cortex 
hypo-activity. 
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In the description of tests of human learned helplessness (section 2.4), it also refers to the 
recent evidence for unpredictably per se having aversive emotional valence. The study reporting this 
finding (Herry et al., 2007) was in fact translational: It also demonstrated that, in mice, temporally 
unpredictable sound pulses lead to increased expression of the immediate-early gene c-fos and 
impaired rapid habituation of neuronal activity in the basolateral amygdala, and to increased anxiety 
readouts on the approach-avoidance conflict tests of elevated plus maze and passive avoidance. 
Therefore, effects of auditory unpredictability need now to be studied at the behavioural and neural 
levels in MDD patients: evidence for increased aversive reactivity would indicate this as a state 
marker that would be clearly amenable to translational study. 
Emotional-cognitive reactivity to negative feedback. There is a recent publication of 
successful application of a probabilistic reversal learning test in rats (Bari et al., 2010), allowing for 
the translational study of the increased negative feedback sensitivity state marker of MDD (Table 2). 
So far, to our knowledge, there is no published method for a probabilistic reversal learning test in 
mice, which would. It will certainly be worthwhile to attempt to develop such a test: For example, 
mice could be trained to respond for reward at two nose-poke operanda that are placed in separate 
locations in a Skinner box. Responding to one operandum (“incorrect”) would be punished by a time 
out at 100% contingency and responding to the other operandum (“correct”) would be rewarded at 
80% contingency and misleadingly punished at 20% contingency. Following 8 correct trials out of 10 
consecutive trials, the response-reward contingency would be reversed so that the previously 
incorrect operandum is now “correct” and rewarded at 80% contingency. As in the equivalent human 
test, major dependent measures would be total number of correct trials, total number of incorrect 
trials, and total number of erroneous lose-shift trials following misleading punishment. 
Emotional-cognitive reactivity to ambiguous stimuli. The establishment in rats and mice of 
operant discrimination tests that require the subject to make a behavioural response that conveys its 
emotional-cognitive assessment - as rewarding or aversive - of a sensorially-ambiguous stimulus 
could well provide validity for the translational study of the MDD state marker of high bias to 
negative expectancy (Table 2). As noted above, the  prime concern here is the judgement aspect of 
cognitive bias (Paul et al., 2005). One such judgement test has been described for rats: Subjects were 
conditioned on two simultaneous tone-stimulus - operant response schedules, where one tone (S+) 
signalled reward (food) following an operant response and a second, distinctly different tone (S-) 
signalled avoidance of punishment (loud noise) by withholding the operant response. Introduction of 
intermediate - and therefore emotional-cognitive ambiguous - tone stimuli allowed for the probing 
of whether the subject anticipated a positive or negative event. Rats that had experienced an 
environment of chronic unpredictable mild stress were less likely to perform an operant response to 
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the ambiguous stimuli (suggesting that they had been classified to the tone that non-ambiguously 
signalled ‘withhold operant response to avoid punishment’), suggesting that they had developed an 
emotional-cognitive bias to expect negative events (Harding et al., 2004). This pioneering 
demonstration that such a test can be acquired by rats and that behaviour in the test is stressor-
sensitive, provides incentive for development of such tests in mice, given their validity with respect 
to an important MDD state marker. 
Effort/reward choice behaviour and physical effort to complete a manual task. Although 
reduced energy/increased fatigability/diminished activity is, according to ICD-10, a core symptom of 
MDD (Table 1), and despite the availability of rodent behavioural tests for measurement of 
psychomotor retardation, very few studies have focussed on rodent models of this MDD state. With 
respect to tests, rats and mice can, for example, be trained and tested in a T-maze apparatus where 
one arm of the maze is consistently baited with a large amount of palatable food (reward) but 
requires energetic behaviour, e.g. climbing, to retrieve it, and the other arm is consistently baited 
with a small amount of reward that is retrieved easily. Non-manipulated rats strongly prefer the 
large, demanding reward (Mott et al., 2009), thereby providing a basis for the study of any 
psychomotor fatigue induced by MDD-relevant genetic and environmental manipulations. As 
described above, relatively rapid reduction in grip strength has been demonstrated in MDD patients, 
and using an operant apparatus analogous to the human dynamometer test combined with positive 
reinforcement, grip strength can also be measured readily in rodents (Connolly et al., 2001). Of 
course, tests of psychomotor performance based on appetitive behaviour for reward can be 
confounded by effects of manipulations on reward sensitivity per se and such effects need to be 
controlled for as much as possible, so as to achieve valid tests of fatigue. 
4. Mouse genetic and environmental manipulations in translational depression research 
4.1. The central importance of manipulations with aetilogical validity in mouse models of 
depression  
 Here we present the fourth and final section of our translational research framework for 
improved face, construct and aetiological validity of mouse models of psychopathological states in 
depression, namely the integrative study of genetic and environmental MDD risk factors in mice. 
Aetiological validity refers to the independent factors that are manipulated in mice and are studied in 
terms of their effects in the behavioural tests described above and on their neurobiological 
underpinnings and correlates. For a mouse study to be aetiologically valid there must be a genetic, 
environmental or environmental x genetic manipulation that is based on epidemiological evidence 
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from MDD patients.5 Genetic manipulations with aetiological validity can be used to investigate their 
effect on analogue MDD endophenotypes, and environmental and ExG manipulations with 
aetiological validity can be used to investigate their effect on analogue MDD state markers. 
Therefore, the combination of a G, E or ExG manipulation with aetiological validity and a behavioural 
test with face and construct validity constitutes a translational mouse model of a MDD 
endophenotype or state marker. Such models can then be used to study the pathophysiology and 
neuropathology of these endophenotypes or state markers, as well as to investigate the effects of 
pharmacological manipulations thereon. Below are presented some relevant examples of studies 
that have investigated the effects of genotypes, environmental stress factors, or environmental 
stress factor-genotype combinations with MDD aetiological validity, on emotional behaviour in mice. 
4.2. The study of effects of valid genetic manipulations on MDD behavioural endophenotypes in 
mice 
As stated above (section 2.3), for six genes there is significant evidence for association of a 
specific polymorphism with MDD: 5-HTT (SLC6A4), DAT (SLC6A3), D4 (DRD4), MTHFR, GNB3, and 
APOE. To-date, mouse studies of these genotypes have yielded equivocal evidence for a direct causal 
contribution to affective phenotypes; two examples are presented here to illustrate this. In the case 
of the human 5-HTT gene, the polymorphism associated with depression is the short (s) 5-HTT gene-
linked polymorphic region (5-HTTLPR-s), which leads to reduced 5-HTT expression and reduced pre-
synaptic serotonin reuptake (Murphy and Lesch, 2008) (section 2.3). In mouse, this neurochemical 
phenotype is modelled by heterozygous 5-HTT constitutive knockout (5-HTT+/-): relative to wildtype 
(5-HTT+/+), 5-HTT+/- mice exhibit low 5-HTT levels (Bengel et al., 1998) and high basal extracellular 
serotonin levels in cortico-limbic-striatal regions (Matthews et al., 2004). However, 5-HTT+/- mice do 
not differ from wildtype on anxiety measures in the elevated plus maze or light-dark box (Holmes et 
al., 2003), nor do they differ from wildtype in their behaviour in the forced swim test (Carroll et al., 
2007). In the human DAT gene, there is a variable number of tandem repeats polymorphism in the 3’ 
untranslated region. The 9-repeat (9R) and 10R are the most common forms of the gene, and the 9R 
form is associated with relatively low DAT expression (Mill et al., 2002) - which would be predicted to 
lead to low synaptic dopamine clearance - and increased risk for MDD (Lopez-Leon et al., 2008). A 
putative model of the 9R geneotype, heterozygote DAT+/- mice, exhibited reduced immobility in the 
                                                          
5
 Just as dependent variables such as those yielded by behavioural tests must possess face validity with respect 
to MDD state markers, so it can be argued that genetic and environmental independent variables possess face 
validity, e.g. does a stressor procedure in mice exhibit similar characteristics to stressors that are risk factors for 
MDD e.g. uncontrollability? Here we put the emphasis on the fact that independent study variables must have 
a demonstrated aetiological relevance to MDD. Nonetheless, we also emphasize that the mouse genetic and 
environmental manipulations used must have face validity. 
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tail suspension test (Perona et al., 2008): this is the opposite of the depression-analogue phenotype 
of increased immobility which has been proposed for this test but, as noted above, the validity of the 
test is questionable. 
4.3. The study of effects of valid environmental manipulations on MDD behavioural state markers 
in mice 
As stated above (section 2.3), environmental stressors associated with MDD comprise 
stressors occurring during development (e.g. childhood abuse, neglect) and adulthood that increase 
vulnerability to MDD and stressors occurring more proximate to the onset of MDD and that could 
trigger the disorder. Accordingly, the development of manipulations of environmental factors with 
MDD aetiological validity in animals is complex. Details of some of the most-studied environmental 
stressors in rat and/or mouse, together with their salient and putative translational characteristics, 
the behavioural tests used to assess their effects, and the resultant behavioural readouts and 
neurobiological concomitants, are presented in Table 3. For example: Chronic unpredictable mild 
stress has been demonstrated to lead to a reduced preference for palatable sucrose solution relative 
to water and increased negative emotional-cognitive bias, in rat (Willner, 1997; Harding et al., 2004). 
Uncontrollable electroshock stress leads, as described above, to an escape deficit in the two-way 
shuttle box and a general deficit in behaviour-outcome expectancy (stress uncontrollability, 
helplessness), in rat and mouse (Anisman et al., 1978; Jackson et al., 1978; Amat et al., 2005). 
Chronic social stress in the form of regular changing of social group composition leads to increased 
anxiety on the elevated plus maze and increased immobility in the tail suspension test, in mouse 
(Schmidt et al., 2007; Sterlemann et al., 2008). Chronic social defeat by physical aggression and the 
threat thereof leads to a reduced preference for palatable sucrose solution and to increased anxiety 
on the elevated plus maze, in mouse (Berton et al., 2007; Krishnan et al., 2007). Early life stress, 
typically in the form of daily maternal separation, leads to reduced incentive motivation for sucrose 
on a progressive ratio schedule and an increased escape deficit following exposure to uncontrollable 
electroshock, in rat (Ruedi-Bettschen et al., 2005; Ruedi-Bettschen et al., 2006). A further important 
factor that emerges from these studies is that of inter-individual variability in reactivity (or resilience) 
to the environmental stressor. Thus, although the mice used for such studies are all wildtype 
individuals of the same inbred strain and are therefore genetically homogeneous, e.g. C57BL/6, they 
can be classified into two groups along one measure of stress reactivity and this predicts their 
behavioural response in subsequent tests. For example, specifically those mice exposed to chronic 
social defeat that exhibited subsequent social avoidance of a conspecific went on to exhibit a deficit 
in sucrose preference (Krishnan et al., 2007); and specifically those mice exposed exposed to chronic 
social stress that exhibited a subsequent chronic elevation in basal corticosterone titres went on to 
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exhibit increased anxiety (elevated plus maze) and increased immobility in the tail suspension test 
(Schmidt et al., 2010). 
    TABLE 3 ABOUT HERE PLEASE 
Some of these same environmental stressors have been studied in terms of their 
neurobiological effects (Table 3). Such approaches not only aim to establish the neurobiological 
mechanism underlying the observed behavioural effects and thereby yield evidence of construct 
validity of the model; they also provide potential new insights into MDD pathophysiology and 
neuropathology. For example, we have already described the evidence that the escape-deficit 
inducing effects of uncontrollable stressors are mediated by impaired inhibitory glutamate-GABA 
signaling from the ventromedial prefrontal cortex to the dorsal raphé nucleus (Amat et al., 2005; 
Robbins, 2005) (section 3.3.). In a mouse study of two-way escape behaviour following inescapable 
footshock exposure, the phenotype of escape deficit was associated with altered substance P 
activity, including increased synthesis in the periaqueductal gray and increased release in the nucleus 
accumbens (Berton et al., 2007). Also in mice, chronic social stress that led to social avoidance and a 
reduced preference for palatable sucrose, also induced hyperactivity of dopamine neurons in the 
ventral tegmental area-nucleus accumbens reward pathway (Krishnan et al., 2007).  
In addition to the study of the neurobiological effects of these complex exogenous stressors, 
another approach has been to experimentally manipulate specific stressor-responsive endogenous 
factors, using delivery via infusion or viral vector. The emphasis with this approach is to focus on a 
certain aspect of the stress response and its potential involvement in changes in cellular signalling 
and gene expression leading to MDD. Examples of endogenous factors studied using this approach, 
and for which there is supportive evidence for aetiological-pathophysiological validity from MDD 
neuropathology, are: (1) Elevated corticosteroid activity in the central nervous system, involving: 
decreased glucose transport, increased glutamate signalling, decreased brain-derived neurotrophic 
factor, and decreased mitogen-activated protein kinase (MAPK) signalling, leading to impaired 
cellular resilience (Duman et al., 1997; Manji et al., 2001). (2) Elevated proinflammatory cytokine 
activity in the central nervous system, involving: reduced serotonin activity, increased glutamate 
signalling, increased microglia, and reduced astrocytes (Müller and Schwarz, 2007). Elevated 
corticotropin releasing factor activity in the central nervous system, involving: MAPK extracellular 
signal-related kinase 1/2 signalling in amygdala and hippocampus (Refojo et al., 2005; Todorovic et 
al., 2009). For the purposes of this review, important points to note are: (1) Such models of 
pathophysiology have typically attempted to explain MDD in its entirety rather than to focus on 
specific state markers/symptoms. (2) The behavioural testing in such studies has typically relied on 
tests of low face and construct validity e.g. forced swim test, tail suspension test. From the viewpoint 
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developed in this paper, we clearly would advocate that these vitally important studies of exogenous 
and endogenous stress factors should focus on specific MDD state markers, and that the contribution 
from animal studies should be based on translational, i.e. valid, behavioural tests of these state 
markers. 
4.4. The study of effects of valid environment-gene manipulations on MDD behavioural state 
markers in mice 
A valid point of criticism of the preclinical MDD research to-date is that the effects of genetic 
and environmental manipulations have been largely studied in isolation from each other. Given the 
wide interest in the ExG model in human MDD research and indeed the important evidence for ExG 
aetiology of MDD (see section 2.3), there is a clear need for more E-G studies using valid mouse 
models. These studies would enable the study of E-G additive effects (E+G), E-G interaction effects 
(ExG) and also E-G protective or resilience (E/G) effects. Certainly in other areas of preclinical 
research, e.g. obesity (which has high co-morbidity with MDD), there is already a significant emphasis 
on E-G studies, e.g. effects of energy rich diet in mice expressing mutations that predispose to 
obesity (Bornstein et al., 2006). There are some important examples of ExG animal models for MDD-
relevant phenoytpes: In the rhesus macaque, for example, the 5-HTT gene exhibits an orthologue of 
the human 5-HTTLPR polymorphism, and the interaction of the -s and -l genotypes with severe early 
life stress in the form of maternal privation has been studied. Macaques with the 5-HTTLPR-s 
genotype that grew up in the absence of the mother and in the presence of peers exhibited a 
relatively increased stress response to social isolation, compared with each of the other ExG groups 
(Barr et al., 2004). In mouse, 5-HTT+/- mice that received low levels of maternal care exhibited a 
reduced latency to immobility in the tail suspension test relative to those that received high maternal 
care, although not relative to WT mice that received low or high maternal care (Carola et al., 2008). 
Although these mice findings are not consistent with the ExG interaction that would be predicted by 
the human study ((Caspi et al., 2003); see above), the approach taken in this study does have 
aetiological validity. As the epidemiological evidence accumulates (e.g. (Ressler et al., in press)), then 
more complex and perhaps more realistic interactions, e.g. ExGxG, ExExG, will also need to be 
studied in mouse models. Furthermore, epigenetic (epiG) events may well also be a major causal 
mechanism in MDD, i.e. the processes whereby E’s impact on methylation, acetylation and 
phosphorylation of histones, on methylation of DNA, and on post-transcriptional gene-silencing 
mechanisms e.g. microRNAs (Mill and Petronis, 2007; Tsankova et al., 2007; Nestler, 2009). 
Accordingly, E-EpiG studies will be required. 
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5. Mouse models with face, construct and aetiological validity as the basis for preclinical treatment 
discovery 
This paper has presented a translational framework to stimulate and inform translational 
research that aims to increase the validity of mouse models for preclinical MDD research and thereby 
increase understanding of MDD and provide a robust basis for the development of novel effective 
treatments. The framework comprises four inter-dependent themes: (1) A depression systems-model 
(Figure 2) presented the causal pathway between human gene-environment (G-E) epidemiology, 
pathophysiology, psycho- and neuropathology, symptoms, and diagnosis. This model depicts why G 
→ neuro-psychology endophenotypes and G-E → neuropsychopathology state markers are the most 
valuable currency of experimental and translational depression research. (2) Some of the human 
neuropsychological tests with translational value/potential that are currently in use for the study of 
these endophenotypes and state markers are presented (Table 2). (3) The analogous behavioural 
tests for mice that are currently available or could be developed are presented (Table 2). Emphasis is 
placed on the fundamental importance of rigorous analysis and demonstration of face and construct 
validity (Figure 3). (4) The fundamental importance of rigorous attention to genetic and 
environmental (Table 3) aetiological validity is presented, so that meaningful G → endophenotype 
and E-G→ state marker (also ExG, ExGxG, etc → state marker) mouse models can be developed and 
studied (Figure 3). As referred to throughout this paper, there is now a tremendous realization of the 
need to increase the translational value of both clinical and preclinical research in depression. As 
schematized in Figure 5, our framework argues that these clinical and preclinical efforts need to be 
aligned and integrated in order that translational progress can be made.  
    FIGURE 5 ABOUT HERE PLEASE 
By establishing mouse models that are valid in terms of aetiological factors and emotional-
cognitive processes, it will then be possible to investigate the neurobiological changes that are 
mediating the MDD-relevant emotional-cognitive effects observed. One important function served 
by the analysis of the neurobiological changes is that they allow the construct validity of the models 
to be tested. That is, by comparing the in vivo and ex vivo findings with the human findings obtained 
via neuroimaging and neuropathology, respectively, it is possible to assess analogy in terms of brain 
areas affected and inter- and intra-cellular processes. The second important function of analysis of 
the neurobiological changes is that they allow for novel discoveries with respect to potential 
pathophysiological and neuropathological processes. With respect to both of these functions of 
neurobiological investigation, technological advances in the study of mouse brain function have 
markedly increased opportunities for translational research. These include high-resolution molecular 
magnetic resonance imaging (MRI) applied to such methods as pharmacological MRI and MR 
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spectroscopy and functional MRI (Rudin, 2009). Furthermore, these translational methods can be 
complemented in mouse studies with in vivo electrophysiology e.g. basal and stimulus-evoked field 
potential and single cell recording (Herry et al., 2007; Herry et al., 2008). Ex vivo neurobiological 
studies, including microarray gene expression studies in specific brain regions of interest (e.g. 
(Krishnan et al., 2007)), allow for the elucidation of the inter- and intra-cellular signalling genes and 
proteins that underlie the analogue endophenotypes and state markers. 
This paper began with the justification that the considerable research into depression to-date 
has failed to identify a single molecular entity which has then been targeted pharmacologically to 
lead to the translational development of a novel antidepressant therapy. To rectify this situation is of 
course the major rationale for proposing a translational research framework. That is, there is a need 
for mouse models with demonstrated face, construct and aetiological validity because only such 
models will allow for insights into depression pathophysiology and neuropathology, and will possess 
sufficient predictive validity to ensure that compound effects on mouse analogue state markers 
translate successfully to therapeutic effects in patients. As emphasized in the framework presented 
here, successful anti-depressant treatments are likely to be those that focus on specific but key state 
markers/symptoms and, in accordance with the personalized therapy approach, the state 
marker/symptom and the underlying neurobiological process that need to be targeted, are likely to 
exhibit inter-individual variation. 
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Figure Legends 
Figure 1. Schema of the incompatibility between the nosological diagnosis of MDD and research 
aimed at increased understanding of MDD pathophysiology and neuropsychopathology. Whilst the 
epidemiological evidence is that gene polymorphisms, environmental stressors, and their 
neurobiological interaction, contribute to MDD pathophysiology, there is no aetiological link 
between these pathophysiological processes and the heterogenous nosological entity of MDD. The 
dashed lines and question mark signify the weak heuristic relationship between nosological 
classification and increased understanding of MDD that would support development of improved 
antidepressant treatments. 
Figure 2. A systems model of aetiology-pathophysiology-pathology inter-relationships in MDD, to 
facilitate neuroscience-psychology-psychiatry dialogue aimed at increased understanding of and 
development of improved treatments for MDD. Gene polymorphisms, possibly in interaction with 
environmental factors, are causally associated with psychological and neural processes – 
endophenotypes - that are non-pathological but do increase the carrier’s vulnerability to develop 
MDD. Life stress events, particularly in individuals exhibiting MDD endophenotypes, induce 
pathophysiological changes in the brain. These pathophysiological processes lead to specific 
emotional-cognitive psychopathologies and underlying neuropathologies i.e. MDD state markers. 
Each MDD state marker underlies, or even itself constitutes, a MDD symptom as listed in DSM and/or 
ICD 
Figure 3. A translational framework for improved validity of mouse models of psychopathological 
states in MDD. Evidence for MDD aetiology (G, E, ExG) needs to inform the aetiological factors 
studied in mice. As schematized in Figure 2, MDD state markers in terms of pathological 
psychological and neural processes need to be the central focus of human research. As depicted 
here, MDD state markers are also essential for translational clinical-preclinical research: Analogue 
psychological and neural state markers can be identified in mice. Using analogous tests in humans 
and mice, these psychological state markers can be quantified. Using analogous brain imaging 
techniques in humans and mice, the underlying neural state markers can also be quantified. The 
dashed lines between Human Test and Mouse Test and Human Psycho-pathology and Mouse Psycho-
changes indicate the levels at which translational research can lead to improved face and construct 
validity of mouse research. The dashed line between Human Neuro-pathology and Mouse neuro-
changes indicates the level at which translational research can lead to improved construct validity of 
mouse research. The dashed line between Human Pathophysiology and Mouse Pathophysiology 
indicates the level at which translational research can lead to improved discovery and understanding 
of pathophysiological processes. The overall outcome of improved face, construct and aetiological 
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validity and improved pathophysiological understanding is indicated as novel therapies i.e. improved 
predictive validity of mouse research. 
Figure 4. Assessing the face and construct validity of two-way escape deficit after uncontrollable 
stress as a test for the state marker of loss of control/helplessness. (A) Exposure to inescapable 
electroshock stress leads to an escape deficit in the two-way shuttle box in rodents. This could be 
due to development of psychomotor inactivity, as observed in rodents exposed to inescapable foot 
shock, or to development of an emotional-cognitive deficit in behaviour-outcome expectancy 
(“helplessness”). Using a triangulation approach with a second test allows for differentiation 
between these two potential explanations (see B). (B) Combining the two-way escape test and the 
signalled-punishment suppression of appetitive behaviour test allows for the accurate assessment of 
the effect of exposure to inescapable electroshock stress. Abbreviations: CS = conditioned stimulus 
e.g. tone that predicts response-elicited punishment, ES = escapable foot shock, IES = inescapable 
foot shock, H1 = alternative hypothesis, NS = no foot shock. 
Figure 5. Clinical and preclinical contributions to translational MDD research. (A) Schema of the 
current nosological system with a weak link between aetiology and symptom, and of the current 
trend in animal-model tests to infer complex states without face, construct and aetiological 
validation. The outcome is a lack of analogy and therefore of translational validity, resulting in lack of 
progress with respect to MDD understanding and treatment. (B) Schema for a functional diagnostic 
system with a strong link between aetiology and state marker, and animal models based on face, 
construct and aetiological validity. The outcome is bi-directional translational validity, resulting in 
progress with respect to MDD understanding and target/therapy discovery. 
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Table 1. Diagnostic symptoms for major depressive disorder (DSM-IV) and recurrent moderate depressive disorder (ICD-10) 
                    
Symptom type   DSM-IV classification    ICD-10 classification 
                    
    At least one of:     At least two of: 
Typical/Core   Depressed mood    Depressed mood  
Typical/Core   Loss of interest or pleasure   Loss of interest or enjoyment  
Typical/Core         Reduced energy/increased fatigability/diminished activity 
    At least four of:     At least three of: 
Common   Weight loss     Reduced concentration and attention 
Common   Insomnia     Reduced self-esteem and self-confidence 
Common   Psychomotor agitation or retardation  Ideas of guilt and unworthiness 
Common   Fatigue/loss of energy    Bleak and pessimistic views of the future 
Common   Feelings of worthlessness or guilt  Ideas or acts of self-harm or suicide 
Common   Diminished ability to think or concentrate Disturbed sleep 
Common Recurrent thoughts of death or suicide  Diminished appetite 
Suicide attempt/plan 
                 
Table(s)
Table 2. Some neuropsychological tests of state markers of depression and their mouse analogues         
Symptom or    Human Test       Mouse Test 
Endophenotype or 
State marker                    
Loss of pleasure (DSM)/enjoyment (ICD) Emotional reactivity/sensitivity to positive (visual) stimuli  Relative reactivity to palatable stimulus vs water 
     (e.g. photos of happy faces) 
Loss of interest (DSM, ICD)  Motivational reactivity to rewarding ($) stimuli   Operant responding for palatable stimulus on effortful 
             reinforcement schedule e.g. variable-interval, progressive ratio 
High reactivity to negative stimuli  Emotional reactivity/sensitivity to negative (visual) stimuli  Emotional reactivity (e.g. freezing behaviour) to discrete 
  (e.g. photos of sad or fearful faces)    stimuli and contexts associated with innately negative 
                                                                                                                                                             (foot shock) stimuli 
Stress uncontrollability, Helplessness Emotional-cognitive reactivity to aversive uncontrollability  Escape behaviour in two-way shuttle box  
(Depressed mood (DSM, ICD))
1          
Signalled-punishment suppression of operant behaviour 
High negative feedback sensitivity  Emotional-cognitive response to negative feedback   Emotional-cognitive response to negative feedback 
2 
(Depressed mood (DSM, ICD))
1
 
High bias to negative expectancy  Emotional-cognitive reactivity to ambiguous stimuli   Emotional-cognitive reactivity to ambiguous stimuli 
2 
(Depressed mood (DSM, ICD)) 
(Bleak and pessimistic views of future (ICD))
1
 
Fatigue/loss of energy (DSM)  Physical effort to complete a manual task (grip strength)  Effort-reward choice behaviour; Grip strength and its fatigue 
Reduced energy/Increased fatigability (ICD)      
                  
1 The state marker – symptom pairing is a proposed “best-fit” rather than a clear relationship between the diagnostic symptom and the state marker 
2 Such a test has been developed for rat and not yet for mouse 
Table(s)
Table 3. Environmental stressors studied for their effects in rodent behavioural tests            
Stressor/   Translational   Behavioural tests/effects  Neurobiological effects   References 
Species /   characteristics 
Control                      
Chronic unpredictable  Chronic (≥ 3 weeks)   Preference for palatable reward (↓) Hippocampus Neuropeptide Y (↓)  Willner (1997) 
mild stress     Unpredictable   Intra-cranial self-stimulation (↓)  Amygdala Substance P (↑)  Moreau et al. (1998) 
Rat, Mouse (adult)  (different stressors x times) Negative emotional-cognitive bias (↑)      Sergeyev et al. (2005) 
Home cage, no manipulation Social threat             Harding et al. (2004) 
Inescapable   Acute (1-2 days)   Two-way escape behaviour (↓)  Dorsal raphe nucleus Serotonin (↑) Amat et al. (2005) 
electric foot shocks  Uncontrollable   Signalled-punishment suppression  Locus coeruleus Noradrenaline (↑) 
Rat, Mouse (adult)  Painful    of operant behaviour (↓)   Prefrontal cortex Glutamate (↓) 
Escapable foot shocks, No foot shocks         Periaqueductal gray Substance P (↑) Berton et al. (2007) 
             Nucleus accumbens Substance P (↑) 
Chronic social defeat  Chronic (2-3 weeks)  Social avoidance (↑)   Nucleus accumbens Dopamine (↑) Krishnan et al. (2007) 
Mouse (adult)   Uncontrollable   Preference for palatable reward (↓) 
Home cage, no manipulation Social subordination  Anxiety on elevated plus maze (↑) 
    Pain 
Chronic social stress  Chronic (≥ 7 weeks)  Anxiety on elevated plus maze (↑) Hippocampus Mineralocorticoid receptor (↓) Schmidt et al. (2007) 
Mouse (adolescent)  Unpredictable   Immobility in the tail suspension test (↑) Hippocampus Glucocorticoid receptor (↓)      Schmidt et al. (2010) 
Home cage, no manipulation Social instability        Basal plasma corticosterone (↑) 
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